World in turmoil, domestic pharma firms target India for healthy growth

Share of India revenue in home-grown firms' consolidated turnover rising over the years

Sohini Das | Mumbai
Last Updated at November 22, 2022 22:39 IST

25 per cent of the Indian drug market is under price control, for the rest, firms can take a 10 per cent hike annually in prices

The share of the Indian market in the overall turnover of pharmaceutical (pharma) companies has risen in the past few years. There are several reasons behind this: pricing pressure in the US generics market, currency volatility in the emerging markets (EMs), and India being the only consistent geography with stable prices and demand.

TO READ THE FULL STORY, SUBSCRIBE NOW NOW AT JUST RS 249 A MONTH.

MONTHLY

₹ 249

Select

ANNUAL

₹ 1799

Select

Best Offer

SMART ANNUAL

₹ 1499

₹ 1799

Opt for auto renewal and save Rs 300

Select

What you get on Business Standard Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
Pick your 5 favourite companies, get a daily email with all news updates on them.
26 years of website archives.
Preferential invites to Business Standard events.